8 October 2024 UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101.
A new prefilled autoinjector pen for diabetics, Ogluo (glucagon) has been launched in Germany by Tetris Pharma, a subsidiary of British firm Arecor Therapeutics. 1 November 2022
Adding to a string of recent research collaborations, Japanese drugmaker Ono Pharmaceutical has signed a drug discovery agreement for drugs in the immuno-oncology field with Swiss biotech Memo Therapeutics (MTx), an innovator in the field of antibody discovery and development. 1 November 2022
US pharma major AbbVie communicated during its third-quarter financial results on October 28, that it has decided to stop the development of cedirogant (ABBV-157), an oral RORg inverse agonist jointly discovered by French firm Inventiva and AbbVie for the treatment of autoimmune diseases. 1 November 2022
The Russian capital Moscow is expected to be one of the centers for the production of new vital and essential drugs in the country already in the short term as its pharmaceutical output is steadily growing, according to recent statements by the Moscow city senior state officials and local media, reports The Pharma Letter’s local correspondent. 1 November 2022
Having soared as much as 164% earlier in the day, shares of USA-based Coeptis Therapeutics closed down 45% at $6.50 on the Nasdaq, after it announced the completion of its business combination with Bull Horn Holdings, a special purpose acquisition company (SPAC). 1 November 2022
Long available in Europe under an emergency nod, AstraZeneca's COVID-19 vaccine, Vaxzevria, has finally been granted full approval in the region. 1 November 2022
Drug-resistant pathogens have increased over the past few years and no longer respond to available antibiotics. A new study in India has noted that infections that were once easily treatable are now more difficult to treat, reports The Pharma Letter’s India correspondent. 1 November 2022
In Boston, Massachusetts, one company is now making significant headway in the development of an innovative treatment for serious disorders of the liver. In this week’s episode of The Pharma Letter Podcast, we are joined by Albireo CEO Ron Cooper, for a discussion of his company’s clinical goals and strategic focus. 31 October 2022
Since 1996 when the tissue plasminogen activator (tPA) – Boehringer Ingelheim’s Actilyse - was approved, there have been nothing but failed attempts at developing a safe and effective treatment for ischemic stroke, according to Pharmazz. 31 October 2022
New top-line data released this morning by US pharma major Bristol Myers Squibb suggest that its already-marketed drug Reblozyl (luspatercept-aamt) should be able to address a larger proportion of myelodysplastic syndromes (MDS) patients. 31 October 2022
Nanomaterials have revolutionized biotherapeutics, functioning in a variety of roles ranging from active ingredients to drug carriers. Although no regulatory definition of nano-based drugs (drug products containing nanomaterials) has ever been established, these drugs have two distinct characteristics:1 31 October 2022
Sino-American biotech BeiGene claims significant progress in its efforts to unlock global opportunities for its Brukinsa (zanubrutinib) with recent regulatory approvals in six Latin American countries. 31 October 2022
There has been an update regarding an ongoing collaboration in neurology between Japanese pharma companies Takeda Pharmaceutical and Shionogi. 31 October 2022
Japanese drugmaker Kyowa Kirin revealed on Friday that is has submitted a New Drug Application (NDA) for tenapanor hydrochloride (KHK7791) to the Japanese Ministry of Health, Labor and Welfare. 31 October 2022
Shares of French biotech Quantum Genomics were decimated on Friday after its revealed efficacy results for firibastat in its Phase III study FRESH in treatment-resistant hypertension (TRH), are non-significant versus placebo. The stock plunged 90% to 0.33 euros. 31 October 2022
Once daily dosing of NCX 470 0.1% met the primary objective of non-inferiority in lowering intraocular pressure (IOP) compared to the standard of care, latanoprost 0.005%, in the 691-patient Mont Blanc Phase III clinical trial in patients with open-angle glaucoma or ocular hypertension. 31 October 2022
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
Sage Therapeutics’ share price fell 11% to $6 in pre-market activity on Tuesday, after it announced disappointing top-line results from LIGHTWAVE. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Bayer has entered into a collaboration with MOMA Therapeutics to develop a small molecule oncology program using the latter’s proprietary KNOMATIC platform. 9 October 2024
The UK has launched a new Regulatory Innovation Office (RIO), with the goal of accelerating new technologies, particularly in sectors like biotech and healthcare, by reducing regulatory barriers. 9 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Some two-and-a-half years after buying the Novo Holdings portfolio company ReViral and its respiratory syncytial virus (RSV) candidate sisunatovir in a deal worth up to $525 million, US pharma giant Pfizer may have signalled an early end to the pricey project. 9 October 2024
US pharma major Bristol Myers Squibb’s recent approval from the US Food and Drug Administration (FDA) for Cobenfy (xanomeline and trospium chloride) for the treatment of adults with schizophrenia is a win for the company. 9 October 2024
Cambridge, USA-based City Therapeutics has announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. 9 October 2024
Zephyrm Bioscience, a Cayman Islands-based biotech, has filed for an initial public offering (IPO) in Hong Kong, seeking to raise additional capital to advance its cell therapy pipeline. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101. 8 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.